- Home
- KULR vs GNLX Comparison
KULR vs GNLX Comparison
Compare KULR & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KULR | GNLX |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8M | 124.8M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KULR | GNLX |
|---|---|---|
| Price | $2.74 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $19.75 |
| AVG Volume (30 Days) | ★ 910.8K | 145.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | 18.10 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,274,028.00 | $8,000.00 |
| Revenue This Year | $64.40 | N/A |
| Revenue Next Year | $105.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $1.99 |
| 52 Week High | $7.49 | $8.54 |
Technical Indicators
Market Signals| Indicator | KULR | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 41.97 |
| Support Level | $2.62 | $2.54 |
| Resistance Level | $3.16 | $2.80 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 8.33 | 13.73 |
Price Performance
Historical ComparisonAbout KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.